Sigma-Aldrich announces successful takeover of Molecular Medicine BioServices

American company Sigma-Aldrich announced on 8 May that it has acquired Molecular Medicine BioServices (MMB), a biopharmaceutical contract manufacturing organisation located in Carlsbrad, California.

With US$12 million in annual revenue, the acquisition of MMB is expected to further enhance the biologics capabilities of Sigma Aldrich's manufacturing group, SAFC Pharma.

MMB has produced clinical-grade drug products for a variety of different cancer indicators including head, neck, prostate and pancreatic cancers, as well as for other therapeutic indicators including Alzheimer's disease and cardiovascular disease.

"MMB's experienced team, capabilities and relationships with key end users, combined with SAFC's global presence and financial strength, will allow us to work together to provide the pharmaceutical industry with better, more specialised, high-quality materials to meet customer needs and demand," said Frank Wicks, president of SAFC.

David Backer, president of MMB, will continue as site director for SAFC's newest business, and all current employees in good standing will be retained.